Amerikanische Gesellschaft für Hirudotherapie

Iliotibial Band Syndrome (Investigational Adjunct)

Investigational adjunct for chronic iliotibial band syndrome refractory to standard physical therapy and load-management; activity modification, eccentric hip strengthening, and corticosteroid injection remain evidence-based.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for iliotibial band syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
Welche Evidenz existiert?
Tier C (investigational). There are no published controlled trials for ITB syndrome. Most cases resolve within 4 to 12 weeks with structured physical therapy focused on hip-abductor and external-rotator strengthening, gait retraining (cadence, hip-drop correction), foam rolling, activity load management, and - if symptoms persist - a corticosteroid injection at the lateral femoral epicondyle bursa. Imaging is reserved to rule out meniscus or other intra-articular pathology when the diagnosis is unclear.
Hauptrisiken
  • Bleeding from each bite site for 6 to 24 hours after the leech detaches
  • Bruising over the lateral thigh for 5 to 10 days
  • Local skin or, rarely, Aeromonas hydrophila infection at the bite site
  • Allergic reaction to leech saliva (uncommon)
  • Delay of evidence-based physical therapy if leech sessions become the primary focus of care
  • Placebo response masking progression of an alternate diagnosis (lateral meniscus tear, lateral collateral ligament pathology)
Wer dies nicht in Betracht ziehen sollte
  • Patients who have not completed at least 8 to 12 weeks of structured physical therapy with a sports-medicine focus
  • Patients with suspected lateral meniscus tear or intra-articular knee pathology pending orthopedic evaluation
  • Patients who received a corticosteroid injection at the site within the past 4 weeks
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients with active dermatitis or broken skin over the lateral thigh
  • Patients currently in active marathon or peak-load training without a scheduled rest period
Was Sie Ihren Kliniker fragen sollten
  • Have we confirmed this is ITB syndrome and not lateral meniscus, lateral collateral ligament, or hip pathology?
  • Have I completed a structured physical therapy program with hip abductor and external rotator strengthening?
  • Have we addressed gait factors - cadence, hip drop, footwear, training surfaces, mileage progression?
  • Has a corticosteroid injection been offered, and how does its evidence compare with this investigational option?
  • Where exactly will leeches be placed - confirm placement is lateral to (not directly on) the tender point?
  • What is the practitioner's plan if symptoms do not improve after 2 to 3 sessions?
  • What is the Aeromonas-prevention protocol?
Wann dringende medizinische Versorgung suchen
  • Sudden inability to bear weight, knee instability, or knee locking (possible meniscal or ligamentous injury)
  • Acute severe lateral knee swelling with warmth (possible septic bursitis)
  • Calf swelling, redness, or warmth (possible DVT)
  • Bleeding from a bite site lasting more than 24 hours
  • Fever, chills, or spreading redness at the bite site
  • Hives, facial or throat swelling, or breathing difficulty

Was dies NICHT bedeutet

  • This is not FDA-cleared for ITB syndrome.
  • No published controlled trials exist; mechanistic rationale alone does not establish efficacy.
  • Leech therapy is not a substitute for hip strengthening and gait retraining, which address the underlying biomechanical cause.
  • It does not address intra-articular pathology such as a lateral meniscus tear, which needs orthopedic evaluation.
  • Anecdotal mention in sports-medicine literature is not the same as evidence; placebo response is high in chronic overuse pain.

Clinical Profile

Category
musculoskeletal
ICD-10
M76.30, M76.31, M76.32
Safety tier
low

Evidence Summary

Iliotibial band syndrome is a common overuse injury producing lateral knee or lateral hip pain in runners and cyclists, caused by friction or compression of the distal iliotibial band over the lateral femoral epicondyle. Evidence-based management: activity modification, load reduction, eccentric strengthening of hip abductors and external rotators, foam rolling and soft-tissue mobilization, gait retraining (cadence increase, hip drop correction), and corticosteroid injection at the bursa-like region for refractory cases. Most cases resolve with structured rehabilitation within 4-12 weeks. No published controlled trials of hirudotherapy exist for ITB syndrome. Local placement over the lateral femoral epicondyle or lateral thigh has been mentioned anecdotally in sports-medicine naturopathic literature without controlled evidence.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Lateral meniscus tear or other intra-articular pathology
  • Recent corticosteroid injection at the site (< 4 weeks)
  • Skin abrasion or active dermatitis at lateral thigh
  • Active marathon training without rest-week scheduling

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Iliotibial Band Syndrome (Investigational Adjunct) — Hirudotherapy Evidence | ASH